Theratechnologies Inc T.TH

Alternate Symbol(s): THTX

Healthcare Biotechnology

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.

TSX:TH - Post by User

Theratechnologies Inc > The prescriber base has doubled for Trogarzo

<< Previous

Bullboard Posts

Next >>

Comment by SPCEO1on Apr 14, 2021 12:29pm

108 Views

Post# 32993264

RE:RE:RE:RE:RE:RE:RE:RE:The prescriber base has doubled for Trogarzo

Since you said "given Thera's track record", you have to conclude the answer is no. But based on my personnel knowledge of the people involved, I would think they were plenty capable. It is a conundrum.

jeffm34 wrote:
In the next couple of years the company will be negotiating much larger financings and potentially billion dollar licensing agreements. Given Thera's track record do you believe they have the proper management in place to execute those agreements and get the best possible terms for shareholders?

FredTheVoice wrote: JEFF this is just short term frustrations view that you are spreading on this board.....

Lets just wait, and I am pretty sure a lot here are ready to say that in two years, with oncology and NASH on the roll, with some results out, TH will see no problem with that 50M your are talking about (convertable...).

You really think TH shares wont be worth more than 15$C a share next year ?

If so, its time to sell and invest in an another company.....

All my respect on a bad day,

BLTA.

FTV.